StockNews.AI
A
StockNews.AI
148 days

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

1. Agilent supported Autolus Therapeutics with FDA approval for AUCATZYL® CAR T therapy. 2. The xCELLigence technology contributed to the potency assay validation for AUCATZYL.

2m saved
Insight
Article

FAQ

Why Bullish?

Agilent's involvement in a successful FDA approval can enhance reputation and sales. Past examples show similar impacts from partnerships in successful biotech approvals.

How important is it?

The announcement positions Agilent favorably in the biotech industry, attracting investor attention.

Why Short Term?

The FDA approval may lead to immediate revenue opportunities. Historical cases indicate rapid market responses following biotech product launches.

Related Companies

AUTLAVLRMRNA
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a.

Related News